Compare Annaly Capital Management, Inc. (NLY) vs Oruka Therapeutics Inc. Common Stock (ORKA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Annaly Capital Management, Inc. vs Oruka Therapeutics Inc. Common Stock — how do they compare? Annaly Capital Management, Inc. trades at $18.36 (market cap $13.69B), while Oruka Therapeutics Inc. Common Stock trades at $76.8 (market cap $5.08B). The key difference: Annaly Capital Management, Inc. is far larger — about 2.7× Oruka Therapeutics Inc. Common Stock's market cap, and Annaly Capital Management, Inc. pays a 16.52% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Annaly Capital Management, Inc. for 92 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| NLY | ORKA | |
|---|---|---|
Market Cap | $13.69B | $5.08B |
Volume | 10,312,599 | 685,276 |
Sector | Real Estate | Health |
52-Week High | $24.40 | $113.08 |
52-Week Low | $17.93 | $26.19 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $135.72B | $4.21B |
Dividend Yield | 16.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Annaly Capital Management (NLY) trades at $18.16, down 0.71% with a bearish technical signal. The mortgage REIT shows strong profitability with 92.77% net margin and 20.66% ROE, trading below book value at P/B 0.91. Recent earnings beat expectations for three consecutive quarters, while analysts maintain a $22 consensus target. The company maintains a $0.75 quarterly dividend, yielding approximately 16.5%.
NLY presents a high-yield opportunity with attractive valuation metrics, though significant risks exist from interest rate sensitivity and portfolio expansion. The stock's current discount to book value and strong analyst buy consensus (57%) suggest potential upside, but investors must weigh the high dividend sustainability against mortgage market volatility and the company's substantial debt load.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →
